1103501-89-8

Usage

Uses

Used in Pharmaceutical Research:
(S)-6-aza-spiro[2.5]octan-4-ol hydrochloride is used as a research compound for its potential therapeutic properties in the development of new drugs.
Used in Cardiovascular Applications:
In the pharmaceutical industry, (S)-6-aza-spiro[2.5]octan-4-ol hydrochloride is used as a therapeutic agent for the treatment of cardiovascular diseases such as hypertension and heart failure, due to its ability to block certain receptors in the body.
Used in Neurodegenerative Disease Treatment:
(S)-6-aza-spiro[2.5]octan-4-ol hydrochloride is used as a potential treatment for neurodegenerative diseases, showing promise in managing the symptoms and progression of these conditions.
Used as an Analgesic:
In the field of pain management, (S)-6-aza-spiro[2.5]octan-4-ol hydrochloride is used as an analgesic, helping to alleviate pain and discomfort in patients.
Used in Synthesis of Other Pharmaceutical Compounds:
(S)-6-aza-spiro[2.5]octan-4-ol hydrochloride is used as a precursor in the synthesis of other pharmaceutical compounds, contributing to the development of a diverse range of medications.

Upstream product

• 1101840-73-6 (S)-4-hydroxy-6-aza-spiro[2.5]octane-6-carboxylic acid tert-butyl ester 
• 1103501-90-1 (S)-6-aza-spiro[2.5]octan-4-ol 
• 108546-98-1 1-allyl-cyclopropanecarboxylic acid tert-butyl ester 
• 1101840-81-6 (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol 
• 1101840-77-0 6-benzyl-6-aza-spiro[2.5]octan-4-one hydrochloride 
• 1101840-76-9 1-[2-(benzyl-tert-butoxycarbonylmethyl-amino)-ethyl]-cyclopropanecarboxylic acid tert-butyl ester 
• 452911-09-0 tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate 
• 1101840-74-7 4-Oxo-6-aza-spiro[2,5]octane-6-carboxylic acid tert-butyl ester 
• 1101840-72-5 tert-butyl 4-hydroxy-6-azaspiro[2.5]octane-6-carboxylate 
• 159635-22-0 3-hydroxy-4-methylene-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 

Downstream Products

• 1101841-91-1 (S)-4-[(E)-3-(3-Chloro-4-fluoro-phenyl)-acryloyl]-1-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-propyl]-3-methyl-piperazin-2-one 
• 1205543-28-7 (S)-4-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 
• 1206600-00-1 (R,S)-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-2-[7-oxo-4-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-butyric acid methyl ester 
• 1206601-20-8 [3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-propyl]-carbamic acid benzyl ester 
• 1206600-57-8 1-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-propyl]-3-methyl-4-(3-trifluoromethoxy-phenyl)-piperazin-2-one 
• 1206601-69-5 [4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-butyl]-carbamic acid benzyl ester 
• 1205542-31-9 (R,S)-4-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-1-methoxycarbonyl-propyl]-5-oxo-[1,4]diazepane-1-carboxylic acid benzyl ester 
• 1205543-14-1 (S)-4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid benzyl ester 
• 1282532-53-9 (3S,6S)-3-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-2-oxo-ethyl]-6-methyl-5-oxo-hexahydro-oxazolo[3,2-a]pyrazine-7-carboxylic acid benzyl ester 
• 1282532-47-1 (3S,5S)-5-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-ylmethyl)-3-methyl-4-oxo-octahydro-9-oxa-2,4a-diaza-benzocycloheptene-2-carboxylic acid benzyl ester 
• 1282532-76-6 (3S,8aS)-6-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-ethyl]-3-methyl-4-oxo-hexahydro-pyrrolo[1,2-a]pyrazine-2(1H)-carboxylic acid benzyl ester 
• 1290050-56-4 (S)-4-[(R,S)-3-hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3-chloro-4-trifluoromethyl-phenyl)-amide 
• 1290050-27-9 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid (3-chloro-phenyl)-amide 
• 1290049-14-7 (S)-4-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3,4-dichloro-phenyl)-amide 

Relevant academic research and scientific papers

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

HETEROCYCLIC COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.